BNTX BioNTech SE March 11, 2026 BMO Maintains Outperform
BMO Capital maintained an Outperform rating on BioNTech SE (BNTX) on March 11, 2026. The firm also lowered its price target to $128 in the same note. We track this as a maintenance of conviction amid updated model assumptions. This change is recorded by StreetInsider and followed a small market move of -0.23% or – $0.21 on the cited timestamp. The phrase BNTX analyst rating frames investor queries and is central to this analysis.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
